191 Introduction: Targeted radionuclide therapy (TRT) is becoming an accepted treatment
modality for patients with advanced metastatic castration resistant prostate cancer (mCRPC) …

Aim Combined 68 Ga-PSMA-617 PET imaging and 177 Lu-PSMA-617 therapy is a precise
targeted theranostic approach for patients with metastatic castration-resistant prostate …

Purpose This translational study is designed to assess the safety, dosimetry and therapeutic
response to a single, low-dose of 177 Lu-EB-PSMA-617 in comparison to 177 Lu-PSMA-617 …

536 Purpose: In prior studies, we synthesized 177 Lu-EB-PSMA by conjugating a truncated
Evans Blue (EB) molecule and DOTA chelator onto PSMA-617, and labeled it with 177 Lu …

Methods: Prospective, analytical and experimental study of mCRPC patients who underwent
doses of 177 Lu-PSMA-617 (7.4 GBq every 6 weeks) at CUDIM in the period October …

Introduction Prostate-specific membrane antigen (PSMA) targeted 225Ac shows promise for
metastatic castration-resistant prostate cancer (mCRPC) treatment. However, variations in …

Simple Summary Imaging plays a crucial role in the accurate staging of prostate cancer.
Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer cells, and …

1276 Purpose: Treatment regimens with predefined treatment cycles of Lu-177-PSMA-617
radioligand therapy (RLT) may be suboptimal in patients with more aggressive high tumor …

Background Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy
(RLT) with 177 Lu-labeled PSMA ligands has achieved remarkable results in advanced …

177Lu-PSMA-617 therapy has shown high prostate-specific antigen (PSA) response rates in
men with metastatic castration-resistant prostate cancer. However, early treatment …